Joint Pain News and Research

RSS

Covidien introduces PENNSAID to the U.S. market

Covidien, a leading global provider of healthcare products, has introduced PENNSAID (diclofenac sodium topical solution) 1.5% w/w to the U.S. market. PENNSAID is the only FDA-approved topical non-steroidal anti-inflammatory drug in a vehicle solution containing dimethyl sulfoxide, a known penetrating agent. It is indicated for treatment of the signs and symptoms of osteoarthritis of the knee(s).

26 Apr 2010

Research roundup: Arthritis racial disparities, hospital mortality data, voters on long-term care

Differences In The Prevalence And Impact Of Arthritis Among Racial/Ethnic Groups In The United States, National Health Interview Survey, 2002, 2003, and 2006 - "Blacks and Hispanics were approximately 1.3 times as likely as whites to have activity limitation, 1.8 to 1.9 times as likely to have severe joint pain, and 1.6 to 1.7 times as likely to have work limitation," caused by arthritis.

24 Apr 2010

New nanotechnology biomedical therapy for joint injuries

Dr. Nirav A. Shah, MD, an orthopaedic sports medicine surgeon affiliated with Palos Community Hospital is the first to design a new nanotechnology biomedical therapy that promotes the growth of new, stronger cartilage to aid in the treatment of joint injuries.

16 Apr 2010

Moving is the best medicine for arthritic pain

The burden of arthritis is greater for African Americans and Hispanics, despite lower prevalence among these groups according to a Centers for Disease Control and Prevention (CDC) report published in the May issue of Preventing Chronic Disease.

16 Apr 2010

Arthritis causes more pain and limitations for African-Americans and Hispanics

Arthritis causes more pain and limitations for African-Americans and Hispanics than for whites, according to a study released today by the Centers for Disease Control and Prevention.

16 Apr 2010

Dry-mouth and dry-eye symptoms often misdiagnosed by healthcare professionals

Results from a recent survey of 400 Sjogren's syndrome patients showed that half of those surveyed experienced common symptoms such as dry mouth or dry eyes for three or more years before receiving an accurate diagnosis from a healthcare professional.

6 Apr 2010

TNS signs revenue sharing agreement to launch dietary supplement products in USA

Total Nutraceutical Solutions, Inc announced today that the company has entered into a revenue sharing agreement to undertake a direct mail marketing program of a proprietary private label compound developed and manufactured by the company for joint pain and inflammation.

31 Mar 2010

Nutra Pharma's Cobroxin pain reliever now available at CVS stores

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy, HIV and Multiple Sclerosis, has announced today that its over-the-counter pain reliever, Cobroxin, is now available for purchase in CVS.

31 Mar 2010

Enobia Pharma unveils findings from first HPP self-reported patient survey at ACMG 2010

Enobia Pharma Inc. unveiled findings from the first hypophosphatasia self-reported patient survey intended to evaluate the burden of illness associated with HPP at the 2010 American College of Medical Genetics Annual Clinical Genetics Meeting.

30 Mar 2010

Queensland rains and floods – boon or bane?

Warnings of floods and rains across Queensland have sparked fears related to Ross River fever among health authorities. Ross River fever is caused by a virus carried by a number of mosquito species. It is usually associated with joint pain and swelling that can last for weeks.

25 Mar 2010

Portable ultrasound device to treat chronic joint pain from arthritis

In recent years, doctors have used ultrasound to effective treat joint pain from arthritis and other ailments without the use of drugs. The drawback to these treatments, however, is that they can only be administered in a doctor's office or clinic, since the ultrasound devices currently used are bulky and expensive.

20 Mar 2010

Pfizer-FRSQ-MSSS Chronic Disease Fund for chronic-disease prevention and management initiatives

The Fonds de la recherche en santé du Québec in partnership with the Ministère de la Santé et des Services sociaux and Pfizer Canada, is announcing the creation of the Pfizer-FRSQ-MSSS Chronic Disease Fund. Established with an investment of $5 million from Pfizer Canada, this research grant program, coordinated by the FRSQ, is open to Quebec-based researchers who work in collaboration with health professionals.

17 Mar 2010

Arthritis drug could be useful for treating patients with type 2 diabetes

Clinical studies of a generic drug called salsalate, widely prescribed for arthritis, now provide early promising results that it may be useful for the treatment of patients with type 2 diabetes as well.

16 Mar 2010

XenaCare Holdings' Cobroxin to be available for purchase in Walgreens

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that its over-the-counter (OTC) pain reliever, Cobroxin, will be available for purchase in Walgreens by May 1, 2010. Walgreens is considered one of the nation’s largest pharmacy chains with 7,162 drugstores located throughout the United States.

11 Mar 2010

Acupuncture may reduce joint pain and stiffness caused by routine breast cancer therapy

A new study, led by researchers at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center, demonstrates that acupuncture may be an effective therapy for joint pain and stiffness in breast cancer patients who are being treated with commonly used hormonal therapies. Results were published in the Journal of Clinical Oncology.

4 Mar 2010

OrthoDynamix' ArthroSteer 3.5mm Ablator for general surgical use receives FDA clearance

OrthoDynamix announced today that it has received FDA clearance for its new device, ArthroSteer 3.5mm Ablator, a mono polar electrosurgical device, for general surgical use, including the orthopedic and arthroscopic applications for resection, ablation, excision of soft tissue, hemostasis of blood vessels, and coagulating soft tissue in, but not limited to the knee, shoulder, and primarily the hip.

3 Mar 2010

Gaucher disease: FDA approves VPRIV

The U.S. Food and Drug Administration has approved velaglucerase alfa for injection (VPRIV) to treat children and adults with a form of the rare genetic disorder Gaucher disease.

26 Feb 2010

World's smallest ultrasound device could offer a new level of home therapy for painful ailments

It looks more like an iPod than a medical tool. But the latest miniature ultrasound device created by Cornell biomedical engineering graduate student George K. Lewis could one day introduce a whole new level of home therapy for arthritis, injury and other painful ailments.

18 Feb 2010

Sales of Cobroxin exceeds XenaCare Holdings' projections for first 45 days of 2010

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, announced today that it has begun distributing and selling Cobroxin through mass food and drug retail chains in the Northeast, Southeast, Middle Atlantic and Midwest regions.

12 Feb 2010

HSS supports Arthritis Foundation's educational campaign for osteoarthritis

Hospital for Special Surgery, (HSS), a world leader in orthopedics and rheumatology, today announced its support of the Arthritis Foundation and Ad Council newly launched campaign, "Moving is the Best Medicine," to raise awareness of osteoarthritis, increase public health education and support breakthrough research.

5 Feb 2010

Joint Pain News and Research

Covidien introduces PENNSAID to the U.S. market

Research roundup: Arthritis racial disparities, hospital mortality data, voters on long-term care

New nanotechnology biomedical therapy for joint injuries

Moving is the best medicine for arthritic pain

Arthritis causes more pain and limitations for African-Americans and Hispanics

Dry-mouth and dry-eye symptoms often misdiagnosed by healthcare professionals

TNS signs revenue sharing agreement to launch dietary supplement products in USA

Nutra Pharma's Cobroxin pain reliever now available at CVS stores

Enobia Pharma unveils findings from first HPP self-reported patient survey at ACMG 2010

Queensland rains and floods – boon or bane?

Portable ultrasound device to treat chronic joint pain from arthritis

Pfizer-FRSQ-MSSS Chronic Disease Fund for chronic-disease prevention and management initiatives

Arthritis drug could be useful for treating patients with type 2 diabetes

XenaCare Holdings' Cobroxin to be available for purchase in Walgreens

Acupuncture may reduce joint pain and stiffness caused by routine breast cancer therapy

OrthoDynamix' ArthroSteer 3.5mm Ablator for general surgical use receives FDA clearance

Gaucher disease: FDA approves VPRIV

World's smallest ultrasound device could offer a new level of home therapy for painful ailments

Sales of Cobroxin exceeds XenaCare Holdings' projections for first 45 days of 2010

HSS supports Arthritis Foundation's educational campaign for osteoarthritis

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News